Clinical Trials · NCT07223983
Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS)
- Phase
- Phase 1
- Recruitment status
- Active Not Recruiting
- Sponsor
- Yale University
- Enrollment
- 4
- Start date
- Mar 2026
- Locations
- 1 site, United States
- Primary endpoint
- Percent weight change